Global X Genomics & Biotechnology ETF (GNOM)

NASDAQ: GNOM · IEX Real-Time Price · USD
15.03
-0.51 (-3.28%)
Aug 9, 2022 10:31 AM EDT - Market open
-3.28%
Assets $246.93M
NAV $15.54
Expense Ratio 0.50%
PE Ratio -11.00
Shares Out 15.89M
Dividend (ttm) $0.01
Dividend Yield 0.04%
Ex-Dividend Date Dec 30, 2021
1-Year Return -37.14%
Volume 43,628
Open 15.44
Previous Close 15.54
Day's Range 15.03 - 15.44
52-Week Low 10.48
52-Week High 25.05
Beta 1.01
Holdings 41
Inception Date Apr 5, 2019

About GNOM

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Asset Class Equity
Region Global
Issuer Global X Mgt
Stock Exchange NASDAQ
Ticker Symbol GNOM
Index Tracked Solactive Genomics Index

Top 10 Holdings

45.27% of assets
Name Symbol Weight
Beam Therapeutics BEAM 5.23%
CRISPR Therapeutics AG CRSP 5.15%
GENSCRIPT BIOTECH CORP 1548.HK 4.78%
Sarepta Therapeutics SRPT 4.70%
Natera NTRA 4.67%
Alnylam Pharmaceuticals ALNY 4.63%
Intellia Therapeutics NTLA 4.22%
BioNTech SE BNTX 4.16%
BioMarin Pharmaceutical BMRN 3.92%
Myriad Genetics MYGN 3.81%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 30, 2021 $0.00651 Jan 7, 2022
Dec 30, 2020 $0.0324 Jan 8, 2021
Full Dividend History

News

Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

A Comprehensive Guide to Genomic ETFs

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

Top ETFs Tracking CRISPR Gene Editing

These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.

Other symbols: ARKGIDNAPBEWDNA

ETF Battles: ARKG Vs IDNA Vs GNOM

Join us for a triple-header to determine the best genomics biotech ETF!

Other symbols: ARKGIDNA

Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan

The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.

Other symbols: GERMIHEVIRSXHE

How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

Snag Next-Generation Tech Exposure with This Genomics ETF

ETF investors looking to get in on the next generation of medical technology may want to give the Global X Genomics & Biotechnology ETF (GNOM) a closer look. Genomic sequencing is already playing a pivo...

Genomics ETFs Surge on a Major Breakthrough in CRISPR Study

The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.

Other symbols: ARKGIDNA

4 ETF Areas Surged Last Week

These four ETF areas were winners last week.

Other symbols: AMLPAMZABDRYBTECBUG

Top-Performing Biotech ETFs of Last Week

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort

In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing.

Other symbols: INDAXBI

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Other symbols: BBCPBESBIOXBI

ETF Battles: ARKG Vs GNOM

Which biotech/genomics ETF is the better play?

Other symbols: ARKG

Can Global X's GNOM Be the Next Big ETF?

Genomics could be the next big thing in the biotechnology space. Similarly, the Global X Genomics & Biotechnology ETF (GNOM) could be the next big fund, and is already up 10% to start the new year.

Top-Performing Biotech ETFs Amid the COVID-19 Crisis

The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.

Other symbols: ARKGBTECIDNAXBI

Get On Board a Growing Biotech Industry With the GNOM ETF

It's one thing to discuss the economics of investing in the biotech sector, but it's another to discuss genomics. The sub-sector of the biotech industry has seen strong growth as evidenced by the over 6...

Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up

Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4% b...

Other symbols: IBBXBI

Healthcare ETFs: Winners & Losers in the Light of U.S. Election

The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.

Other symbols: CNBSIHEIHFIHIPJPXHE

Why You Should Invest in Genomics ETFs

Genomics ETFs have surged of late; here's why

Other symbols: ARKGIDNA

Top Sector ETFs From Wall Street's Best Week in 3 Months

Last week was cheery for Wall Street, with the S&P 500 and Nasdaq recording their best weekly advancement since July.

Other symbols: AMZATANTHCXXSD

Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Other symbols: ARKGIDNAPBE

Buy the Dip With These ETFs Under $20

The recent market rout led by the tech selloff has provided investors a great opportunity to tap the stocks under $20.

Other symbols: BETZEDOCICLNIEZ

Jay Jacobs: These High-Growth ETF Themes Have Seen Triple-Digit Returns In Coronavirus Rally

Jay Jacobs, SVP and head of research and strategy at Global X ETFs, joined the podcast this week to discuss thematic investing and the new Global X Telehealth ETF (EDOC). Plus, we take a look at two ETF...

Other symbols: SNSR

The Genomics Market is Poised for Growth Through 2025

Disruptive technology is always an interesting play for investors to consider and the genomics market is one to watch closely. According to the “Genomics Market – Growth, Trends, and Forecasts (2020-202...

Other symbols: ARKG

Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says

Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.

Other symbols: CLOUHERORYTVGTXLK